Investigational drug · Phase 2
MRG-001
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Alcoholic Hepatitis, Acute Alcoholic Hepatitis.
Phase 2Last checked: Nov 19, 2026Latest source record: Mar 13, 2024 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
6
Any phase or sponsor naming "MRG-001"
First trial start
2024
Sep 1, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MRG-001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Alcoholic Hepatitis
- Acute Alcoholic Hepatitis
Approved drugs for the same conditions: Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "MRG-001" as an intervention, largest first.
- Safety and Preliminary Efficacy Study of MRG001 in Patients With Non-Hodgkin Lymphoma (NHL)Status unknown
Shanghai Miracogen Inc.Industry
NCT05155839 · 108 participants (planned) · Start Jun 25, 2019 · Primary completion Oct 2022
Drug: MRG001 · For: Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)
Sites: Beijing, China; Fuzhou, China; Guangzhou, China · 12 sites in all
MedRegen LLCIndustry
NCT06308926 · 60 participants (planned) · Start Dec 1, 2024 · Primary completion Feb 1, 2026
Drug: MRG-001 (Low-dose); MRG-001 (High-dose) · For: Acute Respiratory Distress Syndrome; Respiratory Failure; Respiratory Distress Syndrome and 2 more
MedRegen LLCIndustry
NCT04646603 · 40 participants (planned) · Start Dec 1, 2021 · Primary completion Mar 31, 2022
Drug: MRG-001; Placebo · For: COVID-19; ARDS, Human; Stem Cells and 1 more
Sites: Baltimore, Maryland
- MRG-001 in Patients With Alcoholic HepatitisNot yet recruiting
MedRegen LLCIndustry
NCT06307522 · 32 participants (planned) · Start Sep 1, 2024 · Primary completion Sep 1, 2026
Drug: MRG-001 · For: Alcoholic Hepatitis; Acute Alcoholic Hepatitis
MedRegen LLCIndustry
NCT05844527 · 10 participants · Start Nov 20, 2023 · Primary completion Sep 1, 2024
Drug: MRG-001; Saline · For: Wound of Skin; Abdominal Wound
Sites: Chicago, Illinois
- MRG-001 in Patients With Amyotrophic Lateral SclerosisStatus unknown
MedRegen LLCIndustry
NCT06315608 · 10 participants (planned) · Start Jul 1, 2025 · Primary completion Jan 1, 2026
Drug: MRG-001 · For: Amyotrophic Lateral Sclerosis; Lou Gehrig Disease; Motor Neuron Disease and 1 more
Newest research
PubMed records naming it or its code names, newest first.
- Mobilizing stem cells and inhibition of autoimmunity synergistically modify autoimmune disease to relieve pain: a potential MRG-001 therapy for rheumatoid arthritis.
Zhang W, Lopez F, Wan M, et al. · Int J Surg 2026
- A phase I, first-in-human study to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics of MRG-001 in healthy subjects.
Ahmadi AR, Atiee G, Chapman B, et al. · Cell Rep Med 2023
Also in development for Alcoholic Hepatitis
- TAK-242Phase 21 trial
Yaqrit Ltd · Acute-On-Chronic Liver Failure, Alcoholic Hepatitis, Liver Cirrhosis, Alcoholic
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.